GHP October 2016

ghp October 2016

www.ghp-magazine.com

Research, Translation, Commercialisation

Having Access to Palliative Care Why a Person’s Death Should Not Be Painful

Lace Up with TRI Take the Lead in Your Clinical Study

Regulatory Heights Inc. The Solution to all your regulatory compliance needs!

Readership from across the world of Health and Pharma

USA/Canada 165448

Europe/UK 17981

South America 11984

Europe 43873

Asia/Pacific 10564

MENA 10606

Please subscribe to GHP Magazine for free through the webage listed below. http://www.ghp-magazine.com/home/subscribe-page-for-free/

ghp

Research, Translation, Commercialisation

editor’s note

this month’s feature 04 News

Welcome to the October edition of Global Health & Pharma, includes the latest news, alongside a variety of exciting features, including a special guest article from the world’s first children’s hospice on why having access to palliative care is something that every person deserves.

Health & Social Care 10 Living and Dying in Pain: Why a Person’s Death Should Not Be Painful 12 Know the Drill 14 High-End Specialist Residential Nursing Care 16 A Complementary and Integrative Approach to Better Health 18 Collaborative, ‘Whole Person’ Health Care 20 The World’s Leading Authority on Cancer Prevention Research

Helen & Douglas House’s CEO Clare Periton goes on to say that advances in technology and medication have enabled drugs to be much subtler now. This progression is invaluable in the sector she believes, and is especially helpful when caring for children and young adults, as they do at Helen & Douglas House.

In addition to a major focus on health & social care, we also feature an insightful section covering innovation and technology. One contributor, Joost Bakker of Scicomvisuals, says that the biotechnology sector provides a truly dynamic environment in which goal-oriented science and bright ideas can flourish. Alongside this, he says that it takes remarkable acumen and drive to excel in this field, which is crucial to develop solutions that really help to deal with the challenges of today.

In research and development news, the Medical Research Council reveals that scientists have been able to shed more light on how the Zika virus works, by sequencing the full-length genome of the virus from a patient in Brazil and studying how a molecule derived from the genome fights the host antiviral response.

I hope that you enjoy reading this absorbing edition.

Jonathan Miles, Editor

inside this issue

Innovation & Technology 22 Collaborations between Pharma and Diagnostic Companies Boost Growth for Neurodiagnostics 24 Visualising Success Research & Development 26 Full Genomic Sequencing of Zika Could Help Unlock Virus’s Secrets

Living and Dying in Pain: Why a Person’s Death Should Not Be Painful We spoke to Clare Periton, CEO of Helen & Douglas House who explains to us how recent evidence shows that some people who receive palliative care can live for longer. Page 10

Translation & Commercialisation 28 Morocco, Poland and Vietnam Earmarked for Financial growth Educatrion & Skills 30 Overseas Doctors Welcome in Scotland 31 Winners’ Directory Deals 32 Deals

“Providing the opportunity for people to live life to the fullest is a lot of what we do, and a life to the fullest is a life with as little pain as possible, regardless of how long that life will be.”

Clare Periton, CEO Helen & Douglas House

Global Health & Pharma, Floor 1, Suite F, The Maltsters, 1-2 Wetmore Road, Burton On Trent, Staffordshire, DE14 1LS Tel: +44 (0) 1234 567 890 | Email: info@ghp-magazine.com | Web: www.ghp-magazine.com

news

Poll Shows Public Back Role for Dogs in Detecting Disease An overwhelming majority of the public support the use of trained dogs in the detection of human diseases, a poll commissioned by Medical Detection Dogs has found. Medical Detection Dogs, a charity at the forefront of training dogs to detect disease, has increasingly gained acceptance and support among the medical community a year on from its launch of two major threeyear cancer detection trials in collaboration with NHS trusts.

Now a YouGov survey of over 2,000 British adults (2,047) suggests that the public would support the training of dogs to a stage where they can start saving lives.

Almost four in five respondents agreed that a dog’s sense of smell can be more reliable a detector than a machine. Dogs are able to smell one part per trillion, the equivalent of one teaspoon of sugar in two Olympic-sized swimming pools. In prostate cancer detection, machines being developed to replace existing tests are only 60% reliable whereas Medical Detection Dogs have achieved a reliability of 93% in training trials.

Over four in five (82%) would be comfortable for doctors to use trained dogs to detect human disease in urine, breath and sweat samples. Nearly seven in 10 (69%) agree that more resources should be allocated to advancing research into using dogs’ sense of smell to help early diagnosis of human diseases.

Claire Guest, CEO and co-founder of Medical Detection Dogs commented, “we are on the brink of something extraordinary here at Medical Detection Dogs. We know our dogs can reliably detect the odour associated with human disease, but we are delighted the public also recognise the potential of our work and want to see more resources go into advancing this technology. Look past the waggy tail and furry

coat; we’re working with a bio sensor that has been in development over 30,000 years.

“Humans and dogs have worked together for tens of thousands of years. They have hunted with us, guarded us and guided us. Now we are opening a brand new chapter in this relationship; we are giving them the chance to save our lives by detecting disease.

The charity, which was founded in 2008 and has had the patronage of the Duchess of Cornwall, is collaborating with local NHS trusts on two major trials into the canine detection of breast and prostate cancer.

The studies, which are due for publication in 2018, will be the most comprehensive pieces of evidence for the technology ever to be produced. In training trials, the dogs have demonstrated a 93% rate of reliability, much higher than many existing tests for cancer.

The charity has received international support for its pioneering work.

In May, it received a grant from the Bill and Melinda Gates foundation to collaborate with Durham University, London School of Hygiene and Tropical Medicine and MRC Unit the Gambia to investigate the detection of malaria using the olfactory power of dogs. www.medicaldetectiondogs.org.uk

4 | ghp October 2016

37% of Mental Health Patients Were Offered No Support to Quit Smoking One in four people in the UK will experience a mental health problem each year according to mental health charity Mind.

Among this population, a shocking 40% will smoke compared to the national average of 16.9%.

According to new data collated by www.vapourlites. com, 38% of mental health sufferers smoke and in contrast to the general population, this has remained steady. Considering that 80% of mental health patients attempt to quit smoking, it is startling to find that 23% of them were advised not to quit and an alarming 37% were offered no support to quit.

A survey conducted by Action on Smoking & Health (ASH) has revealed that a whopping one third of cigarettes in the UK are smoked by people with mental health conditions. Sadly, these individuals are not receiving the support they need from mental health services.

And the shocking statistics don’t stop there. 10% of mental health patients actually started smoking during a hospital stay. The data, collated using figures provided by ASH shows that the more severe the mental health problems, the more likely the sufferer is to smoke - and to become heavily addicted as they rely on the nicotine to relieve stress and anxiety.

The survey examined whether mental health patients felt e-cigarettes might help them to quit smoking - and a conclusive 67% of those surveyed supported the use of e-cigarettes in mental health facilities.

Charles Bloom from Vapourlites commented, “E-cigarettes should be available in health facilities, as no matter who you are, quitting smoking can be a difficult time. E-cigarettes make the process more manageable and have helped so many people already. Considering that medical professionals cite them as an altogether better alternative to smoking, without the harmful chemicals cigarettes contain, there is really no reason why those with mental health conditions shouldn’t be given the option to try them out as a cessation aid” You can view the full study of results here: http://www. vapourlites.com/blog/23-of-mental-health-patientswere-advised-not-to-quit-smoking-by-healthcare-professionals.html

ghp October 2016 | 5

news

School of Medicine Will Address Pressing Healthcare Needs Anglia Ruskin University is planning to open a new School of Medicine for September 2018 to help address the urgent need for more doctors and healthcare professionals in the UK, and specifically in Essex.

The £20 million facility, to be built on Anglia Ruskin’s Chelmsford campus, will be Essex’s first undergraduate medical school. The project has been in development since 2014 and, subject to both approvals from the General Medical Council and the allocation of places from the government, will see the first students start their studies in two years’ time.

Essex has a population of 1.4million and this is set to rise by 20% by 2025. Even with the current population, the national workforce Minimum Data Set for General Practice shows the county is suffering medical workforce shortages across primary care, mental health and acute care. The Mid and South Essex area has the highest percentage of GPs aged over 54 in the country, and the second highest patients-per-GP ratio in the country.

Anglia Ruskin aspires to recruit 50% of the students from the East of England, providing opportunities for the region’s most promising students. Anglia Ruskin is working closely with NHS Trusts and primary care providers across the region to secure placements for students and to ensure graduates have the opportunity to stay in the East of England after they have completed their studies.

The facility will include state-of-the-art skills facilities, specialist teaching space, lecture theatre and a cadaveric anatomy suite, complementing existing skills

facilities and the £3.4 million SuperLab which opened in September 2015.

Dr Ruth Jackson, Pro Vice Chancellor for the School of Medicine Development said, “Essex has a distressed health economy with a shortage of professionals and many of those set to retire in the near future. The county has few undergraduate students who live and train here, and that is what we want to change.

“Anglia Ruskin University has a proud history as one of the largest providers of undergraduate and postgraduate education for healthcare in the East of England over the past two decades. We are passionate about making a difference and we are prepared to make the investment this project requires. Our university has always had a strong commitment to widening participation and we hope to recruit a significant number of students from local schools.

“We have worked closely with a broad range of partners across the regional health economy for the past two years in planning the School of Medicine, including NHS Trusts, primary care providers, local authorities and charities. The development of an Essex-based medical school is widely viewed by these stakeholders as part of the solution to the ongoing issues faced by the region.” www.anglia.ac.uk

6 | ghp October 2016

Pet Obesity Is on the Rise at an Alarming Rate With a 900% increase in cases of diabetes among pets in the last five years, it seems a good time to evaluate what we are feeding them. There has been a 1,161% increase of diabetes cases in cats since 2011, with dogs seeing an 850% rise. This significant increase is the result of owners feeding their pets human food and high-calorie treats, which provides further evidence that our pets are becoming ‘humanised’ and increasingly pampered.

In the UK, it is estimated that half of all dogs and cats are overweight, which is one of the main reasons diabetes in pets is on the up. As with humans, obesity in animals carries with it a whole host of health problems. From cancer and heart disease to degenerated joints, overweight pets are more likely to suffer from a number of related medical conditions. It is important that owners watch out for pet obesity and learn how to treat it.

Andrew Bucher, co-founder and Chief Veterinary Officer at MedicAnimal commented, “our pets are without a doubt valued members of the family. However, it is important to keep treats as treats and not regular snacks to prevent obesity and knock-on health effects.

Many pet treats are high in calories, fat and sugar, which can be bad for them if not regulated. Obesity in animals carries with it a whole host of health problems. From cancer and heart disease to degenerated joints, overweight pets are more likely to suffer from a number of related diseases and will die early.”

A 2015 report published by the Pet Food Manufacturer’s Association (PFMA) found that 73% of vets believe that obesity in pets is indeed getting worse and that the majority of pet owners are seemingly unaware of the life-limiting effects obesity can bring; overweight

animals can have a reduced lifespan of up to two years!

The PDSA’s 20015 Animal Welfare (PAW) report also shows that 58% of the British public believe that severely overweight pets should be removed from their owners, but the feeding problem is also due to too much love. It is common for pet owners to give treats as a sign of affection and it can be difficult to refuse those ‘puppy-dog eyes’ begging for treats.

But it’s not all doom and gloom. While pet obesity is easily preventable, simply reducing portion size won’t work, as this could cause malnourishment over time. There are a number of scientifically formulated nutritional products designed to help with healthy and safe weight reduction but do consult your vet before making any diet or lifestyle changes as they can provide your four-legged friend with a full health check and tailored weight management plan.

Campaigns such as the PDSA’s Pet Fit Club and PFMA’s GetPetsFit have done much to raise awareness of the issue of pet obesity and transform the lives of severely overweight pets. These initiatives are a clear example that education and tailored veterinary support can help reverse obesity in animals.

ghp October 2016 | 7

news

Data on Amgen’s Vectibix® Presented at ESMO 2016 Amgen on 10th October announced results from new retrospective analyses of key studies with Vectibix® (panitumumab) in metastatic colorectal cancer (mCRC) patients. The retrospective analysis of the PEAK study in mCRC patients with RAS wildtype primary tumours of left-sided origin showed that patients receiving Vectibix plus FOLFOX6 as first-line treatment achieved 43.4 months’ median overall survival (OS), an increase of 11.4 months when compared to FOLFOX6 plus bevacizumab.

New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy with or Without Bevacizumab in Metastatic Colorectal Cancer Patients with Tumours of Left-Sided Origin Additionally, for this patient population, the retrospective analysis of the PRIME study showed Vectibix plus FOLFOX4 increased OS by 6.7 months when compared to FOLFOX4 alone. These data were presented at the European Society for Medical Oncology(ESMO) 2016 Congress in Copenhagen (Abstract #89P).

The PEAK and PRIME retrospective analyses, respectively, also showed that mCRC patients with RAS wild-type tumours of left-sided origin receiving Vectibix plus FOLFOX chemotherapy achieved median progression-free survival (PFS) of 14.6 months, an increase of 3.1 months when compared to FOLFOX plus bevacizumab, and 12.9 months, an increase of 3.7 months when compared to FOLFOX chemotherapy alone.

The retrospective analyses found that approximately 80% of tumours originate in the left side of the colon.

Additionally, tumours originating in the right side of the colon are currently associated with a poorer prognosis than tumours originating in the left side of the colon.

In patients with RAS wild-type mCRC with tumours originating on the right side, a subgroup of patients responded to Vectibix and chemotherapy, achieving numerically higher response rates over chemotherapy with or without bevacizumab.

this retrospective analysis of outcomes based on CRC tumour site of origin.

“Data from these retrospective analyses are helping Amgen make important connections between tumour biology and treatment outcomes,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “Tumour sidedness is a surrogate for differences in tumour biology and mutation load, potentially providing physicians with another means to help inform the treatment decisions for patients with metastatic colorectal cancer.”

Colorectal cancer is the second most common cancer in women and the third in men worldwide, with approximately 1.4 million new cases occurring globally each year. In Europe, it is the second most common cancer, with more than 470,000 new cases each year.1 Approximately 80% of all colorectal cancers originate in the left side of the colon and 20% originate in the right side.2 Abstracts are currently available on the ESMO website, here: http://www.esmo.org/Conferences/ESMO-2016-Congress/Abstracts

However, no final conclusions can be made regarding the ability to differentiate treatment regimens for patients with right-sided tumours. The safety profile of the use of Vectibix in combination with FOLFOX-based chemotherapy in mCRC has been previously reported (see summary of EU product safety information below). The aggregate safety data is unchanged by

8 | ghp October 2016

GRAHAM Selected for £4bn P22 Government Healthcare Framework GRAHAM Construction has been awarded a place on ProCure22 (P22), the government’s £4bn construction procurement framework for delivering NHS and social care capital schemes in England. The framework commenced on 3rd October and will run for four years.

The Department of Health has appointed GRAHAM as one of six Principal Supply Chain Partners (PSCPs), along with Kier, Interserve, Galliford Try, BAM and IHP (a joint venture between Vinci and Sir Robert McAlpine).

P22 is the third iteration of the framework that provides the NHS with the tools to deliver improved estate performance while lowering construction and maintenance costs. This new framework is designed to further drive increased efficiency and productivity, streamline the procurement process and produce stronger partnerships between clients, PSCPs and supply chains – all with the aim of supporting enhanced clinical outputs for patients and better environments for staff and visitors.

Keith Hayes, healthcare director at GRAHAM Construction said, “with the P22 framework focusing on quality, value, cost certainty, collaboration, standardisation and a drive for efficiency savings, we are confident that the knowledge and experience gained

from our extensive ongoing healthcare portfolio will help further enhance its outcomes.

“We’re looking forward to working with the Department of Health and our PSCM and PSCP colleagues once the framework comes into place. The combination of the GRAHAM regional office network, carefully assembled specialist supply chain members, BIM focus and extensive experience across the full spectrum of healthcare facilities means we will be able to help NHS clients successfully deliver improvements across their estates and ultimately contribute to optimum outcomes for patients and staff.”

GRAHAM is a privately owned company operating in the construction, asset management and project investment sectors. With a proud heritage where traditional skills and values are fused with professional management, the company has grown to have a turnover in excess of £500 million and employs more than 1,900 people.

In October 2015, GRAHAM Construction was listed at number 26 in the prestigious Sunday Times Grant Thornton Top Track 250, which ranks Britain’s mid-market growth private companies with the biggest sales.

For more information, visit the website: www.graham.co.uk

ghp October 2016 | 9

Living and Dying in Pain: Why a Person’s Death Should Not Be Painful

10 | ghp October 2016

Health & Social Care On the 8th October it was World Hospice and Palliative Care Day, another national awareness day, this time one introduced by the World Hospice and Palliative Care Alliance, consisting of hospices around the country and world. This year the theme is ‘living and dying in pain: it doesn’t have to happen’ - an important message on an even more important day, especially given the recent evidence that statistically proves that some people who receive palliative care can live for longer.

Having access to palliative care, when it is needed, is something that I think every person deserves.

Advances in technology and medication have enabled drugs to be much subtler now, and in addition to this, there is a bigger tool-box for prescribers to use, making pain relief, at least from a medicinal perspective, much more effective. This progression is invaluable in the sector, and particularly helpful in caring for children and young adults, as we do at Helen & Douglas House. Their pain, which often spans a much shorter life, can therefore be treated in a more nuanced and appropriate manner.

Our ability to care for children with serious and life-shortening conditions has improved, and thirty years on from the opening of Helen & Douglas House, there are now a substantial number of children’s hospice services providing excellent palliative care across the UK. They offer world-class medical care to children and their families, enabling respite, empowered choice, and comfort in decisions including how and where to spend final days and weeks together.

In my experience, pain can be made worse by a person’s psychological state, so I believe that holistic approaches are essential. Providing the opportunity for people to live life to the fullest is a lot of what we do, and a life to the fullest is a life with as little pain as possible, regardless of how long that life will be. For those that we care for, every day presents a different challenge.

There is no typical working day for our nurses and carers, who may be presented with extreme ends of the spectrum in the short space of twenty-four hours. They may start the day working a shift in which they carefully plan the logistics of taking a young person with high dependency needs and life limiting conditions to the cinema, with all the dilemmas this poses. By the end of the day, they may finish their shift working with a colleague who is supporting a family as their loved one dies. These opposing sides of patient support make the roles of those at the charity both challenging and rewarding, and emphasises the deferment approaches involved in removing pain from everyday life.

disabled badge or someone coming to mow the lawn, is also vital. This is the type of support that can significantly help reduce stress and therefore pain, returning patients to a more comfortable psychological state, which, can be just as important as relieving pain pharmacologically.

In my experience, wider society, and those outside of the sector assume that pain is the most frightening thing in the process of palliative care, but it could be a number of things. Often we find breathlessness and disorientation considerably more challenging and less fixable than something for which many people take daily medication. Being alert to these harder and less predictable challenges is just one of the many associated challenges of working in palliative care, and achieving the goal of removing pain from the living process too. Living and dying well is therefore not only limited to pain-management, but an issue which requires much more to effectively tackle.

As we passed this year’s World Hospice and Palliative Care Day by reconsidering the implications and indeed the complications of pain, it is vital to remember that a person’s experience of living and dying should not be painful if at all possible, and it is up to those of us who work in end of life care to ensure that this is the case.

Company: Helen & Douglas House Name: Clare Periton, CEO Email: reception@helenanddouglas.org.uk Web Address: www.helenanddouglas.org.uk Address: Helen & Douglas House, 14A Magdalen Road, Oxford, Oxfordshire OX4 1RW Telephone: +44 (0) 1865 794749

For our patients, the experiences of palliative care can be that that mark out their life quality. These are activities that are memorable not for their pain or suffering, but rather for the successful quality of life experienced by the patients involved. Where we cannot promise painless days, we can work hard to make symptoms more bearable. Practical support, ranging from the cinema trips described, to help with organising a

ghp October 2016 | 11

Health & Social Care

1609JC01

Know the Drill Braintree Dental Studio provides high quality advanced dentistry in a comfortable and modern environment. Their team are encouraged to train to a very high clinical level and have undertaken some of the most prestigious postgraduate clinical training around the world.

In addition, they care for all patient groups in a highly invested and inviting dental environment, explains the firm’s Dr. Anup Ladva.

How does Braintree Dental Studio stand out from the crowd?

On patients joining our practice, they immediately see the benefits when compared to the routine dental practices that are currently available. We have taken time and care in establishing ourselves as a practice that provides the highest patient safety compliance, whilst also providing complex dental care. We take referrals from dentists and have the ability to plan dental treatment to very high levels of accuracy using our digital workflows. This includes 3D bone and dental scanning, both of which can be manipulated and designed prior to any surgery.

How is your company performing at present?

Our company is performing well despite the local challenges of being located in a town rather than a city. We have expanded and recently added a 5th dental suite along with a CBCT scanner. We are involved in training young dentists, dental auxiliaries and dental hygienists with some of the best dental education programmes in the UK. What role do your staff play in the successes of your firm?

The staff are important in running the dental surgery in an efficient and friendly way. They have the ability to overcome large hurdles when dealing with the public. They have the ability to put patients at ease and ensure that any clinical or non-clinical questions are addressed prior to any surgery or treatment being carried out. We care and develop our staff by investing in and training them to advance their clinical and management skills.

What challenges does Braintree Dental studio face in the future?

The challenges we see will be based around the extra compliance and governance that may arise from changes in the government NHS contracts. The contract reforms will mean that there will possibly be a change in the team balance to accommodate for revenue/administration requirements as set out by the anticipated contract reforms. This will be difficult to manage and may even include a reduction in revenue for NHS dental practices.

The challenges we face as a company is continuing to grow and provide high quality clinical care whilst the competition grows and begins on a journey of cut price dentistry to encourage revenue growth.

This has become possible due to cheaper alternative components being available from some European and far eastern countries.

Company: Braintree Dental studio Name: Dr. Anup Ladva Email: braintreedentalstudio@gmail.com Web Address: www.cosmetic-dentists-essex.co.uk Address: Unit 4, The Square, Notley Green, Great Notley Braintree CM77 7WW Telephone: 01376 569090

12 | ghp October 2016

Best Dental Practice 2016 - Essex

ghp October 2016 | 13

Our Company in 60 Seconds

14 | ghp October 2016

Health & Social Care

High-End Specialist Residential Nursing Care Austenwood provides high-end specialist residential nursing care, managing complex medical issues including palliative and end of life care. This means that they can manage an individual’s needs from someone simply requiring help with personal care and medication, through to a complex end of life patient, treated with dignity, respect and tranquillity. Peter Evans of Salveo Care Ltd operating Austenwood Nursing Home reveals more about the levels of care this firm offers to its clients, and his aspirations for the future.

How would you define your client base?

Our clients are older people, usually over the age of 65 years but we also can manage individuals with complex conditions over the age of 50 years. Although a parochial business, we admit patients from all over the country.

What makes your firm unique?

Simply the high levels of care where operational profit and excellence of care are not mutually exclusive.

The patient comes first and this is provided by a really excellent and caring body of staff, some of whom have worked here for over 20 years. Consistency with staff is key.

What are the major challenges facing your business at present?

Staffing with nurses, carers and housekeeping staff is a constant challenge. We pay some of the highest rates and benefits and have operated as a Living Wage Employer for long before it became a government buzzword but attracting staff into one of the county’s highest cost areas is a difficult conundrum to overcome. We aim always to employ our own staff who provide such wonderful care to our residents.

Looking ahead, what is the main objective for your business?

We strive to improve on what we do and provide Outstanding care to our residents where we become the beacon of care excellence.

What business or business person do you most admire and why?

I admire any business person no matter how well known, who operates with the interest of their clients or customers at the heart of their business decisions.

Name: Peter Evans Company: Salveo Care Ltd operating Austenwood Nursing Home Email: peterevans@salveocare.co.uk Web Address: www.salveocare.co.uk Address: Austenwood, 29 North Park, Gerrards Cross, Buckinghamshire SL9 8JA Telephone: 01753 890 777

ghp October 2016 | 15

Our Company in 60 Seconds

16 | ghp October 2016

Health & Social Care

A Complementary and Integrative Approach to Better Health If you are looking for solutions to your health care issues, you have found the right place with the company Edwards Holistic Health and Wellness. Providing naturopathic healthcare, by specialising in finding the reason for illness, reversing the health challenges, removing toxins, managing pain and discomfort, instructing you in healthy nutrition along with better habits are the factors that sum up what this company is all about.

In short, they evaluate and provide support and treatment for all types of medical conditions, but we spoke to the company’s Dr. Marty Edwards who told us more about the interesting work of his company.

How would you define your client base?

Our client base is very diversified ranging in age from 3 to 83, from movie stars to the homeless, they come to us from all walks of life.

What makes your firm unique?

I like to think of our practice as not merely an alternative form of health care, but as a complementary and integrative approach to better health.

Looking ahead, what is the main objective for your business?

To care for all those that are seeking traditional naturopathic healthcare, and to educate the population that there are alternative and natural ways to treat and prevent disease and illness in the world we live in today.

Name: Dr. Marty Edwards, ND, CAOM Company: Edwards Holistic Health and Wellness Email: MartyEdwardsND@aol.com Web Address: www.martyedwardsnd.com Address: 529 S. Juniper St., Philadelphia, Pa 19147 USA Telephone: +1 215 966 8774

What are the major challenges facing your business at present?

Being able to balance time and a budget that accommodates the demands of our patient base.

ghp October 2016 | 17

Our Company in 60 Seconds

18 | ghp October 2016

Health & Social Care

Collaborative, ‘Whole Person’ Health Care GSI Health unites patients, doctors, and payers of all kinds, supporting collaborative, ‘whole person’ health care for effective population health management within complex populations. Their innovative solutions deliver the bigger picture of patient care, moving beyond just medical data to integrate social and behavioural information from across the community so that caregivers can manage, analyse, and engage with patients in real time as they move through the care delivery system. Caregivers gain keener insights that improve the quality of care and the overall health of the population, enabling organisations to achieve better outcomes while improving ROI according to the firm’s CEO LeRoy E. Jones who reveals more, in an intriguing interview.

How would you define your client base?

Our client base covers a wide range of healthcare, insurance, and service organisations supporting value-based healthcare programs.

Looking ahead, what is the main objective for your business?

GSI Health was founded with a vision of a future in which the problems of today’s healthcare are solved.

What makes your firm unique?

We believe that combining care coordination with powerful analytics in a single platform creates synergies and insights that enable real population health management success. Our technology integrates and analyses data from across the care continuum to provide a more complete picture with better understanding of the needs and overall health of patients and populations.

We believe that having the right teams assembled to address each patient’s unique needs—and getting the right information to them at the right time—can have a tremendous benefit for healthcare. When care providers just treat a disease instead of treating the whole person—including the medical, social, and behavioural issues that can impact their lives—patients are not receiving the care they need to achieve optimal health.

This innovative approach consolidates diverse, fragmented data in a single comprehensive care plan, with meaningful insights that enable care teams to proactively address gaps in patient care, allocate scarce resources, and strategically identify at-risk patients, ultimately improving patient health.

What are the major challenges facing your business at present?

The healthcare industry is transitioning to a value-based model in which organisations are compensated not for services performed but for keeping patients and populations well. This approach emphasises outcomes and value rather than procedures and fees, incentivising providers to improve efficiency by better managing their populations.

We embraced this transition very early, and built a comprehensive population health platform ideal for value-based healthcare models. Now, we are a leading provider for care coordination tools supporting value-based programs.

Our technology integrates information from across the care continuum and brings the insights out of the back room and closer to the people who are delivering care, empowering caregivers to make decisions about how to best spend their scarce time and resources.

We are working toward a future where data-driven technology optimises overall care delivery, improving the health of entire populations, and solving the problem of uncoordinated, under-informed healthcare being practiced in today’s system.

What business or business person do you most admire and why?

We admire how Steve Jobs was able to develop Apple into arguably the most admired company in the world through emphasis on design and user experience. He delivered on his customers’ dreams, not just their needs.

Name: LeRoy E. Jones, CEO Company: GSI Health Email: info@gsihealth.com Web Address: www.gsihealth.com Address: 1735 Market Street, 53rd Floor, Philadelphia, PA 19103 USA Telephone: +1 888 206 4237

ghp October 2016 | 19

Our Company in 60 Seconds

20 | ghp October 2016

Health & Social Care

The World’s Leading Authority on Cancer Prevention Research World Cancer Research Fund is proud to be the world’s leading authority on cancer prevention research related to diet, weight and physical activity. Indeed, they have developed a global reach in the UK, the USA the Netherlands and Hong Kong.

For the last few decades, they have been a pioneer in research and health information on the link between food, nutrition, physical activity and the prevention of cancer. In an interview, Rachael Gormley elaborates on World Cancer Research Fund’s vision to live in a world where no one develops a preventable cancer.

How would you define your client base?

It is by funding some of the world’s most renowned scientific researchers in the field of cancer prevention and survival that we are now able to better understand how certain lifestyle choices affect our cancer risk.

We also work closely with important decision-makers across the globe to ensure that governments are aware of what action needs to be taken to tackle obesity and improve nutrition. Health professionals have an important role in helping people live healthier lives, and we equip them with the right tools and training to help their patients to do this. We also work with the general public to provide evidence-based information and tips on how to reduce their cancer risk.

What makes your firm unique?

We were the first cancer charity to show the link between diet and cancer prevention, which is now widely accepted in the scientific community. Being the first charity to fund research in this area has made us pioneers in this field, which would otherwise have been largely unknown.

Our Continuous Update Project is our biggest venture, which is the world’s most comprehensive analysis of research on the links between diet, weight, physical activity and cancer. We use these findings to create practical, scientifically-proven recommendations on cancer prevention for use by individuals, health professionals, and governments worldwide.

What are the major challenges facing your business at present?

With so many conflicting headlines about what may or may not affect cancer risk, it can be difficult for indi-

viduals to recognise the importance of our recommendations. The more we get the message across that our recommendations are based on solid evidence, the more we hope people will understand and take on our advice.

Getting governments to take action on issues such as the obesity epidemic or excess alcohol consumption is also a challenge, but one we need to keep working at, as both obesity and alcohol increase the risk of several cancers.

Looking ahead, what is the main objective for your business?

As we look forward to our next 25 years, our scientific research ensures that we will continue to have the latest and most authoritative information at our fingertips, all underpinned by independent expert advice. This will allow our vision for no one to develop a preventable cancer to become a reality sooner.

What business or business person do you most admire and why?

We often work together with Jamie Oliver’s Food Revolution, which is helping children across the world have access to healthy food and receive nutrition education. Jamie’s work and that of his foundation has been instrumental in helping to raise awareness on the importance of tackling childhood obesity and influencing policy to help make this happen.

Name: Rachael Gormley Company: World Cancer Research Fund Email: pr@wcrf.org Web Address: www.wcrf.org Address: 22 Bedford Square, London, WC1B 3HH Telephone: +44 (0) 207 343 4200

ghp October 2016 | 21

Innovation & Technology

Collaborations between Pharma and Diagnostic Companies Boost Growth for Neurodiagnostics The incidence of neurological disorders is escalating and the lack of early diagnostic techniques places the spotlight on innovations in this space. While software platforms are available for processing neuroimaging data, there are limited algorithms for diagnostic and clinical analyses. However, several cloud-based storage platforms exist for exchange and analyses of a vast amount of global neurological data. As companies look to develop quantitative software techniques for the detection and analyses of various neuropathologies, neuroinformatics is poised for a growth spurt in the near future.

The incidence of neurological disorders is escalating and the lack of early diagnostic techniques places the spotlight on innovations in this space. While software platforms are available for processing neuroimaging data, there are limited algorithms for diagnostic and clinical analyses. However, several cloud-based storage platforms exist for exchange and analyses of a vast amount of global neurological data. As companies look to develop quantitative software techniques for the detection and analyses of various neuropathologies, neuroinformatics is poised for a growth spurt in the near future.

The new study, Diagnostic breakthroughs for neurodegenerative diseases (http://frost.ly/qs), a part of the TechVision (Medical Devices & Imaging) subscription, finds that while neuroimaging techniques continue to be the gold standard for neurodiagnostic applications, innovations in biomarker-based diagnostics and integrated neuroinformatic tools will drive the future of this sector. Clinical neuropathologies such as Alzheimer’s and Parkinson’s diseases are likely to have the largest market impact on diagnostics in the near future.

There is an increased collaboration between the pharmaceutical and diagnostic sectors for patient selection during clinical trials, which is fuelling the growth of the companion diagnostic market for neurological disorders. This means that the companion diagnostic market will mirror the growth pattern of the cancer diagnostic sector, expanding the opportunities for diagnostics developers. Advancements in biomarker

studies will aid in early diagnosis and enable timely clinical interventions.

“As it is difficult to offer a conclusive diagnosis using a single technique, neuroimaging techniques are most often used in combination with other technologies or as an adjunct to the clinical diagnosis of neurological diseases,” said TechVision research analyst Vandana Iyer. “Besides, there are very few software platforms that can integrate and accurately analyse the data obtained from a wide variety of neuroimaging modalities.”

The need of the hour is convergence across the biomarker, neuroimaging and informatics segments.

Innovations that enable seamless workflow integration across diverse neurodiagnostic modalities will help overcome technological challenges and widen the reach of the diagnostics. The standardisation of global neuroinformatic clusters will further enable data sharing and analysis.

Currently, several assay platforms are available for the detection of neurological biomarkers, especially for diseases such as dementia and Alzheimer’s Disease.

New biomarker discoveries and advanced diagnostic platforms for Parkinson’s disease, traumatic brain injury and other dementias are expected in the near future. An important emerging trend is the use of optical scanning techniques for detecting retinal biomarkers for neurological diseases.

“Overall, rapid advancements in hybrid neuroimaging platforms have improved the sensitivity and quan-

22 | ghp October 2016

titative accuracy of neurodiagnostic evaluations for numerous neurodegenerative disorders,” noted Iyer.

“Neuroimaging modalities will continue to be one of the major neurodiagnostic tools across research and clinical communities.”

Frost & Sullivan’s global TechVision practice is focused on innovation, disruption and convergence and provides a variety of technology based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth. View a summary of the TechVision program by clicking on the following link: http://ifrost. frost.com/TechVision_Demo. www.frost.com

ghp October 2016 | 23

Innovation & Technology

Visualising Success Scicomvisuals is a highly innovative company, who develop all kinds of visuals, from detailed infographics describing clients’ technologies to compelling cover illustrations, professional scientific posters and animations.

From my experience, the biotechnology sector provides a truly dynamic environment in which goal-oriented science and bright ideas can flourish.

Alongside this, there is enormous acumen and drive to excel, which is crucial to develop solutions that really help to deal with todays’ challenges.

Where Scicomvisuals comes in, is communicating across the ground-breaking ideas and discoveries that occur in the industry. The biotech industry presents its work to, and interacts with, a range of audiences, such as investors, B2B, principal investigators and patients and so on. As such, the ability to successfully communicate the essence of complex scientific concepts and products in a clear and convincing way (to these different audiences) is crucial for the success of the company. Clear visuals are extremely helpful to convey these messages, and Scicomvisuals has the right background and expertise to accomplish this.

Scicomvisuals is very much a one-man band, as I am the only staff member. However, in addition to developing images myself, I work closely with animators, movie editors, (web) designers and communication strategists that help me to carry out my ideas and concepts. With this active and flexible network of experts in all areas of scientific communication, Scicomvisuals can ensure versatility, efficiency and a cost-effective project approach.

What makes us truly stand out is there are not many companies with a clear focus on content visualisation aimed at clients in biotechnology and university. Scicomvisuals builds on deep scientific understanding of biomedical research, with over 20 years of experience in different areas of fundamental research as well as product development. With well over 10 years of experience in biotech industry, Scicomvisuals offers broad experience in all areas of product positioning, with services including graphic design, but also scientific writing, education, and public relations.

Nonetheless, Scicomvisuals is still a young company and was established only three years ago. During this short period of time, we have already been able to attract many national and

international clients, ranging from research groups at university to (private as well as public) biotech and pharma companies in the biomedical and agricultural sector.

Looking further ahead, progress in the biotech sector is moving really fast. At the same time, the possibilities to visualise content has grown rapidly as well. To ensure visualisations remain relevant and focused, it is important to stay up-to-date with major developments in science and design.

Ultimately, I think the biggest driving factor behind the success of the company is that I simply love what I do. It is great to be able to combine my scientific background and expertise with my passion for visualisation and design. To me, developing an illustration, infographic or animation that shows the essence of a technology or scientific concept is a true joy!

Company: Scicomvisuals Name: Joost Bakker Email: Joost@Scicomvisuals.com Web Address: www.Scicomvisuals.com Address: Duivendrechtsekade 85A, 1096AJ Amsterdam, The Netherlands Telephone: +31 (0)6 415 13 558

24 | ghp October 2016

Biotechnology - Solving Global Challenges

ghp October 2016 | 25

Full Genomic Sequencing of Zika Could Help Unlock Virus’s Secrets Scientists have been able to shed more light on how the Zika virus works, by sequencing the full-length genome of the virus from a patient in Brazil and studying how a molecule derived from the genome fights the host antiviral response.

26 | ghp October 2016

Research & Development The research, led by the MRC-University of Glasgow Centre for Virus Research, studied a Zika virus isolated from a patient with classic symptoms and shows the full genomic sequence of the virus, including non-coding regions. Importantly, the research also identified a Zika virus-derived molecule that inhibits an important part of the host’s immune system, which may be key to understanding how the virus causes disease.

The study, recently published in the journal PLOS Neglected Tropical Diseases, was supported by the UK Government and Brazilian partners through the Newton Fund and undertaken in collaboration with a group of international colleges, including in Brazil.

The team compared the genome sequence from this South American Zika virus isolate, which was obtained from a patient in Recife, with other available Zika sequences. They then looked at the non-coding regions of the sequence which are often missing from other sequences, and detected a portion of the viral genome in infected cells called sfRNA. This is also detected in infections by related viruses such as dengue, and the authors described ZIKV sfRNA as having a similar function to those already described as it acts by inhibiting specific parts of the host cell’s antiviral response.

They suggest this study highlights the particular importance of studying patient-derived viruses and comparing them to laboratory cultured viruses, which could mutate and therefore not provide as accurate a picture of the current Zika virus epidemic.

Dr Alain Kohl, leader of the Kohl Group at the MRC-University of Glasgow Centre for Virus research, said, “we have used the information from a Brazilian isolate, which we obtained from our colleagues in Brazil and fully characterised it in collaboration with them, to identify a virus-derived molecule that inhibits a very important part of the host antiviral response system.

“It is particularly important to show this with sequence information as close as possible to the patient-derived virus, as virus strains that are adapted in cell culture may start to mutate. This information is important for understanding the pathogenesis of Zika virus infection but may also be useful for the design of attenuated viruses for vaccine studies in the future.”

The authors hope that the full-length sequence of this patient derived Zika virus will support efforts to combatting the virus. They also expect the detection of the immune system inhibiting molecule will be important to further understand the virus and how it interacts with its host.

Zika virus is a mosquito-transmitted arbovirus.

Although previously poorly investigated, the virus has recently caused large scale outbreaks in French Polynesia in 2013, New Caledonia, the Cook Islands and Easter Island in 2014 and the Americas in May 2015, beginning in Brazil.

The outbreaks have also been characterised by an increased prevalence of neurological syndromes, such as Guillain-Barré syndrome and microcephaly. As of April 2016 the WHO announced that 60 countries had reported transmission in the escalating epidemic, which originated in Bahia, Brazil in 2015 and has so far resulted in over 1.5 million suspected cases.

Dr Jonathan Pearce, head of infections and immunity at the MRC said, “this study demonstrates the unparalleled importance of cross-border working in the face of a global health threat such as Zika. With the help of the Newton Fund, our researchers in the UK were able to get to work with colleagues in Brazil well ahead of the virus being declared a global public health emergency. Together they have gained a much deeper understanding of how the infection develops, and in-depth insights like this is exactly what we need if we are to develop successful approaches to combat the disease.”

Universities and Science Minister Jo Johnson added, “this ground breaking research gives us a far greater understanding of the Zika virus and will help protect millions of people in the developing world from the devastating effects of this disease. Working closely with Brazilian counterparts, our world leading scientists at the University of Glasgow have demonstrated how the government’s £1.5bn investment in the Global Challenges Research Fund brings together the best scientific minds to tackle serious global problems such as the Zika virus.”

The study was led by the University of Glasgow in collaboration with colleagues from the Federal University of Pernambuco, Brazil, University of South Bohemia in the Czech Republic, Yale University and the Institut Pasteur de Dakarin Senegal.

The study, ‘Full genome sequence and sfRNA interferon antagonist activity of Zika virus from Recife, Brazil’ is published in PLOS Neglected Tropical Diseases. The work was funded by the MRC, FACEPE (Fundação de Amparo à Ciência e Tecnologia de Pernambuco), the Czech Science Foundation and the Czech Research Infrastructure for Systems Biology. www.mrc.ac.uk

Dr Claire Donald, the MRC-University of Glasgow Centre for Virus research said, “this work shows that Zika virus acts in a way that is comparable in some respect to what we know about host immune response antagonism for related viruses such as dengue and West Nile viruses.

“Comparing our isolate with other Zika viruses shows that they are very similar to each other at the genetic level. Therefore, it is important for us to understand what factors are involved in the development of disease as well as identifying the key differences between the strains. This may allow us to pinpoint potential outbreaks of concern in the future.”

ghp October 2016 | 27

Translation & Commercialisation

Morocco, Poland and Vietnam Earmarked for Pharma Growth Professional services consultancy Procorre has identified Morocco, Poland and Vietnam as growth hotspots for ambitious businesses and specialist consultants in the pharma sector in the next six months.

Procorre, which works with clients to manage the life cycle of pharmaceutical projects across the globe, has seen enquiries for pharma project support steadily grow this year from a number of emerging markets in Africa, Eastern Europe and Asia. Procorre is expecting activity to increase further towards the end of 2016 and into 2017.

James Alexander, director of global mobility at Procorre said, “while the growth of the pharma sector in the emerging markets is being driven by the usual suspects that make up the BRIC countries (Brazil, Russia, India and China), we are seeing an increasing number of requests to support pharma projects in less obvious markets which already have an established pharma industry.”

The common themes in the development of these pharma markets centre around rapid population growth, a burgeoning ‘middle-class’ and healthcare reforms, underpinned by investment in their domestic pharma industries.

Procorre’s analysis of the market has identified the following growth hotspots: • Morocco - the Moroccan government has highlighted pharma as one of the industries that will boost its economy as part of its Industrial Acceleration Plan. The plan sets out measures to develop Morocco’s pharma industrial base and export capabilities by forming partnerships with other African nations. This will help the country to become a pharma hub for companies keen to serve Africa with the creation of a direct export platform to reach the rest of the continent.

• Poland - there are a range of legal changes on the horizon in Poland where specialist pharmaceutical and healthcare experience could be in demand.

These include a planned programme of free drugs and medical devices for persons aged over 75 years; a mandatory vaccination against pneumococcal disease; and the launch of Poland’s National Plan for Rare Diseases.

• Vietnam - figures from BMI Research show the Vietnamese pharma market is expected to grow from US$4.2bn to $7.2 billion by 2020. However, there are some hurdles to overcome for the sector where experience and expertise will be at a premium. These include regulatory issues, such as inadequate intellectual property regimes and the underlying problem of corruption among healthcare officials. There is also a significant variation in pricing across the country which needs to be tackled to create a more stable market.

Alexander added, “with big pharma companies like Novartis, Sanofi and Astra Zeneca all investing in emerging markets through acquisition or local partnerships, we are seeing an increasing need for specialist consultants and project teams who can apply best practice from other markets to create consistently high standards. As well as medical and scientific roles, there is a demand for expertise in supporting roles including legal, technical and financial posts.”

In addition to pharma, Procorre works with global clients to deliver projects in a variety of sectors including construction, energy, IT, financial services and technology. www.procorre.com

28 | ghp October 2016

ghp ghpNovember October 2016 2016| 29 | 29

30 30| ghp | ghpNovember October 2016 2016

Education & Skills

Overseas Doctors Welcome in Scotland Scotland’s Health Secretary, Shona Robison, said on 4th October that doctors from abroad will be welcome to train and work in the NHS north of the border. Ms Robison condemned comments from the UK Government this morning that overseas doctors will only be able to stay in the NHS until they are replaced by UK doctors.

Ms Robison said, “these are irresponsible comments that will hamper NHS efforts to recruit doctors to vacancies and training places now – and that in turn could have a real impact on patient care.

“As such, the UK Government’s position is short-sighted in the extreme. Medical professionals from outside this country have played a vital and valued part in our NHS for decades, and continue to do so, and their contribution should not be dismissed in this way.

“In Scotland we want the best and the brightest from around the world to stay, build their careers here and contribute to the economy and our society. Of course it is also very important to invest in our workforce at home too. That is why we have already announced an additional 50 medical student places in Scottish Universities from August 2016, and a new Graduate Entry Medical programme with up to 40 places available.

“Our young doctors want good quality, attractive training places which offer rewarding experiences and flexible working. But it has also long been a common practice that young doctors go abroad to experience the different opportunities and challenges of health services across the world – we shouldn’t deprive them of these experiences, because the UK Government’s actions also risk shutting down such opportunities for our own young medics.” www.gov.scot

ghp ghpNovember October 2016 2016| 31 | 31

Lace up with TRI. Take the lead in your clinical study.

TRI expedites your clinical study start-up to minimize costs and avoid delays.

Visit www.tech-res.com or call 301.897.1724 for more information.

32 | ghp October 2016

Winners’ Directory

Healthcare & Pharma Leading Expert - USA Company: Ocean Tomo Name: Kristi Stathis Email: kstathis@oceantomo.com Web Address: www.oceantomo.com Address: 200 West Madison St., 37th Floor, Chicago, IL 60606 Telephone: +1 312 327 4400

ghp October 2016 | 33

Deals

PATRIZIA UK Welcomes Becton Dickinson at Winnersh Triangle PATRIZIA UK, manager of the award-winning Winnersh Triangle, announces that it has secured the letting of 44,000 sq ft of Grade A office space to global medical technology company Becton Dickinson (BD) at the business park near Reading. Becton Dickinson is due to enter three floors of the newly constructed speculative development at 1030 Eskdale Road in Spring 2017.

Prominently located at the western end of the park, 1030 Eskdale Road reached practical completion in February of this year and is a major four-floor development, comprising a total of 61,780 square feet.

BD’s move to Winnersh Triangle sees the consolidation of the firm’s existing UK sites in Oxford and Basingstoke. Strutt and Parker and Vail Williams represented PATRIZIA to secure the ten-year lease, and JLL acted for BD. The deal leaves just third floor availability at 1030 Eskdale Road, comprising 16,000 sq ft of prime office space.

Mike Fairbourn, UK general manager for BD said,” the move to the new site at Winnersh Triangle will free up more time to focus on our customers as it will prevent duplication and the inefficiencies of running two, separate sites and bring together all our functions.

This is a key enabler for our growth strategy for the future. The new offices will be home for commercial operations for all BD businesses in the UK, as well as support functions, technical services and a new Innovation Centre to host customers.”

“Becton Dickinson is the latest international name to join us at Winnersh Triangle and we look forward to welcoming them to the park,” said Will Lawrie, PATRIZIA commercial director. “Our development provides this prestigious company with first-rate office

accommodation in a location which has excellent transport connections and capacity for continued growth and expansion.

“The creation of this new office scheme, with its landscaped communal space for the enjoyment of all our occupiers, reflects PATRIZIA’s investment in the park as one of the premier spaces for businesses in the region.” Winnersh Triangle, named Business Park of the Year at the Thames Valley Property Awards 2016, provides office, industrial, data centre, R&D and amenity space over a total of 1.46 million square feet.

Easily accessible by road just off junction 10 of the M4, Winnersh Triangle also benefits from its own train station within walking distance. In addition to the café, on-site amenities include a four-star hotel with restaurant, café, conference facilities and a range of leisure facilities, plus a retail store, and nursery.

Winnersh Triangle was acquired in July 2013 with funds managed by Oaktree Capital Management LP and real estate investor PATRIZIA UK Ltd. Visit www. winnershtriangle.co.uk for further information, and www.patrizia.ag, plus www.oaktreecapital.com

34 | ghp October 2016

Inotec AMD Limited Appoints New CEO Cambridge based Inotec AMD Limited was pleased to announce in late September the appointment of Chad Bateman as its new Chief Executive Officer.

Inotec AMD is a maker of mobile medical devices designed to heal chronic, hypoxic wounds that afflict millions of sufferers around the world every year.

The global wound-care market is projected to grow to $18.3 billion globally in 2019, driven in part by changing life styles and ageing populations in many countries. There are some 400 million diabetes sufferers around the world, some 60 million of whom are likely to develop a lower limb ulcer. As more than 90% of wounds suffer from a lack of oxygen, the launch of NATROX™ addresses this serious concern with a simple, cost-effective application which treats a broad spectrum of chronic health problems.

Chad Bateman brings on board a proven track record of driving profitable revenue growth. Most recently, he was vice president & general manager - Europe and a member of the extended global leadership team of Acelity, a global leader in wound care and regenerative medicine. Chad has more than twenty years’ experience in sales and marketing, working in organisations such as Olympus and CR Bard Inc., the last seven years of which have been in senior executive positions within the wound care industry where he is highly regarded in the sector.

Dr Adrian Parton MBE, chairman of Inotec AMD said, “the board of directors are pleased to announce the appointment of Chad Bateman who will be starting his new role as CEO of the company in October and we believe that his extensive experience of the wound care market will help the Company drive the growth of Inotec AMD’s novel oxygen therapy products on a global basis”.

Mr Bateman commented, “I feel privileged to be joining Inotec AMD at such an exciting time for the organisation. The ever changing global health and care environment offers exceptional opportunities for new and innovative technologies, like Natrox™, to positively impact on existing patient pathways and outcomes.

I feel particularly passionate about finding unique ways to help patients to heal quickly, improving quality of life; whilst reducing the capacity burden on health economies. My aim is for Inotec AMD to be a valued partner in our evolving wound care environment. It is time to make a difference.”

Since raising its Series A round led by VC fund Amadeus Capital Partners, in April 2016, Inotec AMD has strengthened its sales teams across a number of key territories and has appointed Shona Macdonald as business director for UK and Ireland. Ms Macdonald has many years of experience in the wound care market, having most recently been business director – UK & Ireland at Molnlycke.

ghp October 2016 | 35

Deals

Ventas Issues Secured Debt Financing Commitment for Ardent Health Services to Merge with LHP Hospital Group Ventas, Inc. announced that it has issued a commitment to provide secured debt financing in the amount of $700 million to a subsidiary of Ardent Health Services in connection with Ardent’s agreement to acquire LHP Hospital Group, Inc., also announced recently. Terms of the purchase were not disclosed. The transaction is expected to close in the first quarter of 2017, pending customary regulatory reviews and approvals.

To complete the purchase of LHP, Ventas is providing a commitment to make a five-year LIBOR-based loan, guaranteed by Ardent’s parent company, and bearing an initial interest rate of approximately 8%. Ardent will also receive a significant equity contribution from its majority owner, an affiliate of Equity Group Investments (EGI). The transaction is structured to enable Ardent to maintain its strong balance sheet and potential for future growth and investment.

“This commitment is aligned with our position as the premier capital partner to leading senior living and healthcare providers and our strategy of building a formidable, high quality hospital business,” said Ventas chairman and chief executive officer Debra A. Cafaro.

“The LHP acquisition validates our investment last year in Ardent’s experienced management team and scalable infrastructure, and its ability to consolidate the large, fragmented hospital sector.”

“We are excited by Ardent’s acquisition of LHP, which expands Ardent’s business by 50% and creates the second largest private, for-profit hospital operator in the United States with over $3 billion in revenues. This transaction enhances Ardent’s scale and diversification by adding a high-quality portfolio with significant market share in attractive markets. Ardent will also benefit from LHP’s strong margins, excellent payor mix, significant synergy opportunities and outstanding joint venture partner relationships with leading not-forprofit and academic medical centers. This accretive, well-structured loan will enhance Ventas’s ability to drive reliable growth and income from our diversified portfolio for the benefit of shareholders.”

Ventas expects the Loan to be accretive to 2017 normalised funds from operations on a leverage neutral basis.

Ventas expects to fund the transaction using proceeds of asset sales and loan repayments, cash on hand and other capital sources. The acquisition agreement between

Ardent and LHP and Ventas’s Loan commitment are subject to customary conditions to closing and approvals. There can be no assurance that the acquisition of LHP will occur or that Ventas will fund the Loan.

Following the completion of Ardent’s acquisition of LHP, Ardent will benefit from significant scale and diversification, operating 19 high-quality hospitals with more than 3,200 beds across six states and employing approximately 18,000 employees, including more than 475 physicians. With LHP, Ardent will also gain significant relationships with outstanding joint venture partners, including leading not-for-profit and academic medical centers such as Ascension, Hackensack Meridian Health and Portneuf Health Care. Existing Ardent management will lead the combined company with the assistance of key LHP executives, and expects to realise meaningful synergies in the transaction.

Headquartered in Plano, Texas, LHP is owned by affiliates of the private equity firm CCMP Capital Advisors, LLC and the CPP Investment Board as well as certain members of management and its board of directors.

Ventas owns substantially all of Ardent’s current real estate, including 10 of its 14 hospitals and related medical facilities. Ardent is owned by an entity consisting of an affiliate of EGI, Ardent management, and Ventas, which owns a 9.9% equity stake.

Ventas, Inc., an S&P 500 company, is a leading real estate investment trust. Its diverse portfolio of approximately 1,300 assets in the United States, Canada and the United Kingdom consists of seniors housing communities, medical office buildings, life science buildings, skilled nursing facilities, specialty hospitals and general acute care hospitals. Through its Lillibridge subsidiary, Ventas provides management, leasing, marketing, facility development and advisory services to highly rated hospitals and health systems throughout the United States.

36 | ghp October 2016

Deals

Edgemont Capital Partners Completes Sale of Florida Emergency Physicians to TeamHealth Edgemont Capital Partners, L.P., a leading independent investment banking firm providing merger and acquisition advisory services to healthcare companies, announced that it acted as exclusive financial advisor to Florida Emergency Physicians Kang & Associates, M.D., Inc. in the sale of the company to TeamHealth Holdings Inc. The transaction closed on October 1st 2016 and was led by Jeff Swearingen, managing director, co-founder of Edgemont, and head of the firm’s physician services group and Luke Mitchell, managing director.

Based in Orlando, Florida, FEP is the exclusive emergency medicine staffing provider for 11 facilities spanning five counties within the Florida Hospital health system. FEP comprises approximately 150 physicians and 100 advanced practice clinicians who provide care for 600,000 patients each year. FEP is the largest independent Emergency Medicine physician group in the state of Florida and has served the Florida Hospital system for over 45 years.

“Right from the start, Jeff and the Edgemont team demonstrated a strong understanding of the emergency medicine business and a real commitment to providing great service and the right advice,” said Dr. Jorge Lopez, chief executive officer of FEP. “Edgemont’s market insight and strong execution resulted in a great transaction for FEP’s shareholders, with a partner that will provide the tools and resources to better serve the emergency medicine needs of Orlando.

We are grateful to the Edgemont team for its expert advice and guidance throughout the sale process.

Edgemont’s professionalism and dedication to this engagement, and the depth of its industry experience resulted in a competitive process that brought us an outstanding partner.”

Edgemont’s role as FEP’s exclusive advisor is the firm’s tenth closed transaction on behalf of hospital-based physician groups and management companies and fourth in emergency medicine. Edgemont has now served as exclusive advisor to emergency medicine practices and management companies representing over 5 million annual emergency room visits.

“Independent, high quality physician practices of scale are seeking the highest level of quality and experience in the financial advisors they hire. Edgemont is unsurpassed in its track record of achieving the best transaction outcomes for its independent physician practice clients,” added Mr. Swearingen. “No other investment banking firm has represented more large and mid-sized independent hospital-based physician groups in sale transactions, and Edgemont is the only investment bank that has represented independent groups in sale transactions with all of the publicly-traded hospital-based specialty providers, including EmCare, MEDNAX, Sheridan and TeamHealth.”

Associate Reid Petersen and two analysts completed the Edgemont transaction team. Brent Hill and Amanda Jester of Waller Lansden Dortch & Davis, LLP served as legal counsel to FEP.

38 | ghp October 2016

Regulatory Heights Inc. We are the Solution to all your regulatory compliance needs!

Do you have a pharmaceutical, generic, biologic, biosimilar, OTC drug, medical device, natural health product, herbal medicine, dietary supplement, veterinary drug, cosmetic or food product? Do you need regulatory applications for clinical investigations, product licensing or post market amendments filed with international regulatory authorities (for example in North America, EU, China, Japan, Australia, NZ)? Do you need clinical trial documents designed or safety reports filed with regulatory authorities that are good clinical practice (GCP) or good vigilance practice (GVP) compliant?

Do you have a facility for animal studies and need good laboratory practice (GLP) certification? Do you have a facility for the manufacturing, packaging, testing, labeling, import, distribution or wholesale of the above products or their active ingredients? Perhaps you need these facilities to be good manufacturing practice (GMP) compliant and licensed, as stipulated by the regulatory authority in your region of business? Or perhaps you have a pharmacy that needs licensing as an outsourcing facility with US FDA?

www.regulatoryheights.com

LI160015

Canadian based Regulatory Heights Inc. is headed by CEO & President, Rachelle D’Souza, who has effectively serviced several multi-national and start-up companies in the above industries and has successfully licensed various medical products and facilities with international regulatory authorities. At Regulatory Heights Inc., we constantly monitor the current regulatory environment and utilise regulatory strategies to help our clients facilitate their market approvals, cut costs, mitigate risks and further product innovation. Articles and webinars by our CEO on the latest international regulatory developments are published on-line by professional regulatory associations, webinar hosting platforms and industry magazines around the world. Regulatory Heights Inc. is the recipient of industry awards for its service. We believe in providing quality service at an affordable price!

Deals

Durbin Appoints Todd Galles as Business Development Principal in US Durbin, one of the world’s leading specialist medical suppliers and distributors of pharmaceuticals, has appointed Todd Galles to be its business development principal in the US. Mr Galles will be working to develop and grow Durbin’s client portfolio in the US.

Durbin has made great strides in the US, thanks to a rapidly growing clinical trial supply and Managed Access business driven by its US acquisition last year, and recently won the UK Export Excellence Award for Export Excellence in the Americas. The appointment of Mr Galles reflects Durbin’s desire to continue its progress both in the US and globally.

“Durbin has an important role to play in this global industry,” Mr Galles said. “To be a strong global player and industry leader in Europe, effective companies need to be strong in both the Americas and Europe.

There are a lot of challenges to operating worldwide, but there are even more opportunities. As long as you’re flexible – which Durbin is – there’s a bright future if you can adjust your business to meet the evolving needs.

“Durbin has made a huge resource commitment in the US, and I’m excited to help shape its growing operations here. The company recently opened a US facility in the Gulf Coast which adds customer service, regulatory support, warehousing and other services, further complimenting European operations. We are growing staff with a number of key new positions in the near-term in the US. I am delighted to be part of and play a big role in the US expansion.”

patients with previously unmet medical needs all over the world. US expansion will play a key role in providing enhanced global services for our clients.”

Mr Galles has an extensive background in the life science industry more than 30 years of experience in sales, marketing, business development and executive management in the pharmaceutical and biotech fields. Previous companies include Syntex Laboratories, Dey LP, Santen, Genentech, BioMarin and Dow Pharmaceutical Sciences. Todd has also served on numerous industry and company advisory boards.

Robert Donnell, head of business development at Durbin, commented on the appointment, “Todd has supported business development outreach in the US part-time for Durbin for more than two years, so now we’re delighted to have him on-board fulltime. Todd brings a huge amount of experience and enthusiasm to the role, and I look forward to continuing to work with him to develop and grow our US business.” www.durbin.co.uk

Mr Galles continued, “Durbin is a champion of meeting unmet medical needs – it can distribute products globally to treat patients in need and get them innovative medical therapy. No distribution challenge is too tough – if there’s a way, Durbin can provide the service. I’ve been so impressed by the service Durbin offers, and that was a big appeal to me.

“To continue to develop the relationship between the US, Europe and the rest of the world is something I’m excited to be involved with. There are lots of small- and medium-sized companies that might need help making the jump to work in Europe and other regions around the world, and that’s something we can provide through our managed access programs (MAP). This is a prime example of a Durbin service that adapted to meeting marketplace needs. MAP service programs are delivering innovative therapies to

40 | ghp October 2016

HP160001

Renew your Beauty Through your Health!

Derma Beauty Spa & Medical Clinic is a family business born in 2010 with the purpose of providing services in the field of beauty, weight loss and rejuvenation.

With this philosophy we have become a benchmark of trust and quality beauty services, wellness and personal care.

By the mixture of result and member references we have demonstrated and proven our experiences and abilities in the field of cosmetology. Keeping us in our guests preference, we have the latest techniques and personally designed treatments for every need and skin type, products and high quality machines, in Derma Beauty Spa & Medical Clinic you will remain in family.

dermabeautyspa.com

1609JC01

Dedicated to offer you one of the best quality omega-3 health supplements in the world For more than 20 years we have specialized in OMEGA3 products.

It’s this long experience that makes us different, which makes us into the internationally recognized ”omega-3 experts”.

www.beps-shop.com